Elevated Expression of Lipoprotein-Associated Phospholipase A2 in Calcific Aortic Valve Disease Implications for Valve Mineralization

被引:104
|
作者
Mahmut, Ablajan [1 ]
Boulanger, Marie-Chloe [1 ]
El Husseini, Diala [1 ]
Fournier, Dominique [1 ]
Bouchareb, Rihab [1 ]
Despres, Jean-Pierre [2 ]
Pibarot, Philippe [2 ]
Bosse, Yohan [2 ]
Mathieu, Patrick [1 ]
机构
[1] Univ Laval, Grp Rech Valvulopathies, Lab Etud Mol Valvulopathies, Quebec Heart & Lung Inst,Res Ctr,Dept Surg, Quebec City, PQ, Canada
[2] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ G1V 4G5, Canada
关键词
apoptosis; calcific aortic valve disease; ectonucleotide pyrophosphatase/phosphodiesterase 1; lipoprotein-associated phospholipase A2; lysophosphatidylcholine; protein kinase A; valve interstitial cells; LOW-DENSITY-LIPOPROTEIN; LDL OXIDATION; A(2); INFLAMMATION; STENOSIS; ACETYLHYDROLASE; PYROPHOSPHATE; INHIBITION; PHOSPHATE; PLASMA;
D O I
10.1016/j.jacc.2013.05.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to document the presence and role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD). Background CAVD is a chronic disorder characterized by pathological mineralization and remodeling. Studies have indicated that human CAVD tissues are infiltrated by lipids and that inflammation may play a role in the pathobiology. We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAVD and may play a role in the mineralization of valve interstitial cells. Methods We have documented the expression of the phospholipase A2 family of genes in aortic valves by using a transcriptomic assay. Messenger ribonucleic acid and protein expression were confirmed in aortic valves explanted from 60 patients by quantitative polymerase chain reaction and immunohistochemistry, respectively. The effect of lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization of valve interstitial cell cultures. Results Transcriptomic analyses of CAVD and control nonmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic valves. Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quantitative polymerase chain reaction, immunohistochemistry, and enzymatic Lp-PLA2 activity. The number of Lp-PLA2 transcripts correlated with several indexes of tissue remodeling. In vitro, lysophosphatidylcholine increased the expression of alkaline phosphatase, the ectonucleotide pyrophosphatase/phosphodiesterase 1 enzyme, sodium-dependent phosphate cotransporter 1 (encoded by the SLC20A1 gene), and osteopontin. We then showed that lysophosphatidylcholine-induced mineralization involved ectonucleotidase enzyme as well as apoptosis through a protein-kinase-A-dependent pathway. Conclusions Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role in the mineralization of valve interstitial cells. Further work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD. (C) 2014 by the American College of Cardiology Foundation
引用
收藏
页码:460 / 469
页数:10
相关论文
共 50 条
  • [41] Cloning, expression, and purification of lipoprotein-associated phospholipase A2 in Pichia pastoris
    Zhang, FJ
    Wang, YP
    MOLECULAR BIOTECHNOLOGY, 2006, 33 (01) : 29 - 36
  • [42] Cloning, expression, and purification of lipoprotein-associated phospholipase A2 in Pichia pastoris
    Fujun Zhang
    Yiping Wang
    Molecular Biotechnology, 2006, 33 (1) : 29 - 36
  • [43] Elevated plasma lipoprotein-associated phospholipase A2 activity is associated with plaque rupture in patients with coronary artery disease
    Liu Chuan-fen
    Qin Li
    Ren Jing-yi
    Chen Hong
    Wang Wei-min
    Liu Jian
    Song Jun-xian
    Li Li-jun
    CHINESE MEDICAL JOURNAL, 2011, 124 (16) : 2469 - 2473
  • [44] Role of lipoprotein-associated phospholipase A2 in predicting risk of cardiovascular disease
    Myerson, Merle
    MAYO CLINIC PROCEEDINGS, 2007, 82 (07) : 888 - 888
  • [45] Concentration of Lipoprotein-Associated Phospholipase A2 in Patients With Ischemic Heart Disease
    Noruzbaeva, A. M.
    Osmankulova, G. E.
    Aldashev, A. A.
    Mainazarova, E. S.
    KARDIOLOGIYA, 2016, 56 (01) : 49 - 50
  • [46] Lipoprotein-Associated and Secretory Phospholipase A2 in Cardiovascular Disease: The Epidemiological Evidence
    Koenig, Wolfgang
    Khuseyinova, Natalie
    CARDIOVASCULAR DRUGS AND THERAPY, 2009, 23 (01) : 85 - 92
  • [47] Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease
    Hu, Yun
    Li, Ting-ting
    Zhou, Wei
    Lu, Ting-ting
    Li, Feng-fei
    Ding, Bo
    Liu, Bing-li
    Xie, Xiao-jing
    Ma, Jian-hua
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 194 - 201
  • [48] Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection
    Eckard, A. Ross
    Longenecker, C. T.
    Jiang, Y.
    Debanne, S. M.
    Labbato, D.
    Storer, N.
    McComsey, G. A.
    HIV MEDICINE, 2014, 15 (09) : 537 - 546
  • [49] Lipoprotein-associated phospholipase A2 level in patients with Behcet's disease
    Orem, A.
    Yayli, S.
    Arica, D. A.
    Akcan, B.
    Yucesan, F. B.
    Bahadir, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (03) : e289 - e293
  • [50] Lipoprotein-Associated Phospholipase A2 as a Risk of Coronary Disease in Statin User
    Chung, Hyemoon
    Kim, Myung-Hyun
    Lee, Byoung Kwon
    Kwon, Hyuek Moon
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (07): : 39S - 39S